SynthesisJournal of managed care & specialty pharmacy2025
A systematic review of the applications of the real option value of medical technologies in oncology.
Synthesis in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReal option value (ROV) offers an innovative paradigm to evaluate the dynamic value of medical technologies, particularly in cancer, by capturing the value of extending patient survival to access future innovations. Despite its potential, the application of ROV in medical technologies in oncology remains underexplored.
objectiveTo synthesize existing evidence on the application of ROV in medical technologies in oncology.
methodsA comprehensive search of PubMed, ScienceDirect, and Web of Science was conducted to identify peer-reviewed studies published in English from January 2000 to May 2024. In the search query, a combination of keywords related to "real option value" and "cancer" was used. Key data extracted included study characteristics, objectives, ROV modeling technique, and primary findings. The Consolidated Health Economic Evaluation Reporting Standards 2022 checklist was used for quality assessment of the studies.
resultsA total of 13 of 165 studies assessed the ROV of medical therapies, with a primary focus on melanoma, lung cancer, and prostate cancer. ROV was modeled from the ex post and ex ante perspectives. The methodologies employed vary, with common forecasting approaches including the Lee-Carter model to project future decreases in mortality rates, fitting Cox proportional regression models on administrative claims data, or estimating the approval likelihood of early pipeline drugs based on data from early randomized clinical trials.
conclusionsThe ROV represents a critical dimension in evaluating medical technologies in oncology, where innovation is rapid. The implications of ROV extend beyond oncology, with the potential to influence funding, pricing, and access decisions in other disease areas as well. However, challenges such as oversimplification of assumptions for forecasting, methodological consistency, and lack of standardized framework remain pervasive. This systematic review underscores the need to integrate ROV into Health Technology Assessment practices to inform resource allocation and policy decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.